Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Amgen - The Untold Story

How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.

Barchart

Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

Barchart

Stock Indices Fall from Early Highs and Settle Mixed

The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -0.17%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.83%. September E-mini S&P futures (ESU26 ) fell -0.19%, and September E-mini Nasdaq futures...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Supported by Stellar Earnings

The S&P 500 Index ($SPX ) (SPY ) today is up +0.31%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.03%. September E-mini S&P futures (ESU26 ) are up +0.33%, and September E-mini Nasdaq futures...

Barchart

Strong Earnings Push the S&P 500 to New Record High

The S&P 500 Index ($SPX ) (SPY ) today is up +0.46%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.74%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.51%. September E-mini S&P futures (ESU26 ) are up +0.50%, and September E-mini Nasdaq futures...

Barchart

SpaceX Could Swing $204 Billion After Earnings

Earnings are set to hit the tape in a tight window on Tuesday, and the options market is already sketching out how much volatility traders expect once results and guidance land, according to Benzinga Pro.

Benzinga

Drugmaker Amgen discloses data breach involving patient health information

On July 29, Amgen determined the incident ‌was material, based ⁠on ⁠its evaluation of how many files appeared to be affected and the possibility that the information in those files could be sensitive, it said in a regulatory filing.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Are Wall Street Analysts Bullish on Amgen Stock?

Amgen has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart

Amgen Recalled Nearly 1 Million Bottles of Corlanor for Heart Failure: Check if You Have an Affected Lot

Amgen recalled 934,577+ bottles of Corlanor (ivabradine) in June 2026 over foreign substance on tablets. Check your lot number — and do not stop the drug without your doctor.

Medical Daily

Amgen Earnings Preview: What to Expect

Amgen is set to report Q2 earnings next month, with analysts expecting a single digit EPS decline.

Barchart

Colorado was the first state to cap a drug’s price – then a federal court stepped in

Colorado is one of a handful of states with a review board for drug prices and one of only four with a board empowered to set upper limits on what state agencies, insurers and other purchasers may pay or be reimbursed for certain high-cost drugs dispensed to patients in the…

The Conversation

Your Insurance Plan May Be Pocketing the Drug Coupon Card Meant to Help You Pay for Medication

Nearly 40% of ACA marketplace plans use copay accumulators to pocket drug coupon cards meant for patients. Here is how to check your plan and protect yourself.

Medical Daily

The Clinical Trial That Supported Tavneos for ANCA Vasculitis Was Just Retracted

NEJM retracted the Tavneos ADVOCATE trial on June 29, 2026, after FDA found altered patient data. Patients should not stop Tavneos without a doctor — here's what's known.

Medical Daily

Nearly 1 Million Bottles of a Heart Failure Drug Were Just Recalled — Check Your Medicine Cabinet

Amgen recalled ~934,577 bottles of Corlanor (ivabradine) for heart failure after foreign substance was found. The FDA classified it Class II. Check your lot number now.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Getting past the pilot: Why so many AI test projects have trouble scaling

Business leaders from Salesforce, Amgen, and Thomson Reuters took a hard look at AI pilot projects to understand why some thrive and some flail.

MarketBeat

The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

MarketBeat

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Amgen (NASDAQ:AMGN) executives said the company’s first-quarter performance supports its view that 2026 can serve as a “springboard year,” with growth products helping offset increased competition for the denosumab franchise and other losses of exclusivity. Speaking at a Goldman Sachs event, Peter

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide. Peter Griffith, executive vice president and chief financial

Fortune

The CEO who loves AI autodidacts — and desperately needs his experts

Bob Bradway bet on AI before almost anyone else in biotech. Now Amgen is reaping the rewards — and wrestling with what it means for its scientists.

Barchart

Amgen Stock: Is AMGN Outperforming the Healthcare Sector?

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Kiplinger

Stocks Grind Higher on Good Fundamentals: Stock Market Today

The stock market is a forward-looking mechanism, and what it sees at the bottom line carries greater weight right now than geopolitical uncertainty.

Barchart

Why Wall Street Thinks This Dividend Stock Could Jump 30%

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Kiplinger

S&P 500 Hits New High on Apple Earnings: Stock Market Today

Apple rounded out a big week of mega-cap earnings on a high note, sending two of the three main equity indexes to new highs on Friday.

Barchart

What to Expect From Amgen's Next Quarterly Earnings Report

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.